biostudies-literatureMolina-Alejandre MAsociación Española Contra el CáncerThermoFisherMinistry of Science and InnovationInstituto de Salud Carlos IIIFEDERComunidad de MadridBMSAndalusian GovernmentEuropean Union’s Horizon 2020 research and innovation programmeEuropean Regional Development Funde009762https://www.ebi.ac.uk/biostudies/studies/S-EPMC11492944biostudies-literatureUnknown12(10)<h4>Background</h4>Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on perioperative chemoimmunotherapy (ChIO) efficacy or response mechanisms in the context of HLA class I defects.<h4>Methods</h4>Baseline HLA class I tumor status (HLA-deficient (HLA-DEF) or HLA-proficient (HLA-PRO)) was determined by DNA LOH combined with immunohistochemistry for protein levels in tissue of 24 patients with NSCLC treated with perioperative nivolumab plus chemotherapy from NADIM trial (NCT03081689). We integrated HLA tumor status with molecular data (programmed death-ligand 1 (PD-L1), TMB, TCR repertoire, TILs populations, bulk RNAJournal for immunotherapy of cancerPerioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.PMC11492944PIPF-2022/SAL-GL-25283TCR sequencingPI22/01223Ayuda Predoctoral Madrid 2023Group CTS-143PI23/01054CLARIFY 875160PI19/01652B-CTS-410-UGR-20NADIM Clinical TrialRTC2017-6502-1 &apos;INmunoSIGHT&apos;CP23/00044PID2020-115087GB-100CPP2022-009545 &apos;STRAGEN-IO&apos;RTC2019-007359-1 &apos;BLI-O&apos;Massuti BMolina-Alejandre MAptsiauri NParra ERMartin-Lopez JProvencio MCasarrubios MCasal-Rubio Jde Castro JMartinez JMCobo MNadal EBarneto Aranda ISierra-Rodero BMunoz-Viana RInsa AMartinez-Marti AViteri SWistuba IIRodriguez-Abreu DCalvo VRuiz-Cabello FGarrido FMegias DMartinez-Toledo CPerea FCruz-Bermudez AfalsePerioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.<h4>Background</h4>Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on perioperative chemoimmunotherapy (ChIO) efficacy or response mechanisms in the context of HLA class I defects.<h4>Methods</h4>Baseline HLA class I tumor status (HLA-deficient (HLA-DEF) or HLA-proficient (HLA-PRO)) was determined by DNA LOH combined with immunohistochemistry for protein levels in tissue of 24 patients with NSCLC treated with perioperative nivolumab plus chemotherapy from NADIM trial (NCT03081689). We integrated HLA tumor status with molecular data (programmed death-ligand 1 (PD-L1), TMB, TCR repertoire, TILs populations, bulk RNA2024-01-01T00:00:00Z2024 Oct2026-07-15T13:04:14.853Z2025-04-04T22:47:44.936ZS-EPMC114929443942812610.1136/jitc-2024-009762